| abstract |
Racemic or enantiomerically pure 4-pyrrolidine derivatives, processes for their preparation, pharmaceutical compositions comprising said derivatives, and their use in the prevention and treatment of a disease that is mediated by the monoamine oxidase B inhibitor, in particular Alzheimer's disease and senile dementia. Claim 1: Compounds of the general formula (1), wherein: R1 is halogen, halogen (C1-6) alkyl, cyano, alkoxy (C1-6) or halogen-alkoxy (C1-6); R21, R22, R23 and R24 independently of each other are selected from the group consisting of hydrogen and halogen; R3 is -CONHR5, -CH2CN, -CN or -NHR6, and R4 is hydrogen; or R3 is hydrogen and R4 is -CONHR5, -CONHR5, -CH2CN, -CN or -NHR6; R5 is hydrogen or (C1-3) alkyl; R6 is -CO-C1-6 alkyl or -SO2-C1-6 alkyl; and n is 0, 1, 2 or 3; as well as individual isomers, racemic or non-racemic mixtures thereof. |